An anti-inflammatory cell-free collagen/resveratrol scaffold for repairing osteochondral defects in rabbits

Acta Biomaterialia

Volumn 10, Issue 12, 2014, Pages 4983-4995

  Wang, Wei ^a   Sun, Liang ^a   Zhang, Pengfei ^a   Song, Junfei ^a   Liu, Wenguang ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

Acellular; Anti inflammation; Collagen; Osteochondral damage; Resveratrol

Indexed keywords

BODY FLUIDS; BONE; CARTILAGE; COLLAGEN; DEFECTS; DEGRADATION; FREE RADICALS; GENES; POLYMERASE CHAIN REACTION; RESVERATROL; SCAFFOLDS (BIOLOGY);

ACELLULAR; ANTI-INFLAMMATION; ANTI-INFLAMMATORIES; CELL-FREE; CHONDROCYTES; IN-VIVO; INFLAMMATORY CELLS; OSTEOCHONDRAL; OSTEOCHONDRAL DAMAGE; OSTEOCHONDRAL DEFECTS;

STEM CELLS;

1,1 DIPHENYL 2 PICRYLHYDRAZYL; AGGRECAN; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGENASE; COLLAGENASE 3; CYCLOOXYGENASE 2; GLYCOSAMINOGLYCAN; INTERLEUKIN 1BETA; PHOSPHATE BUFFERED SALINE; POLYACRYLIC ACID; REACTIVE OXYGEN METABOLITE; RESVERATROL; TRANSCRIPTION FACTOR SOX9; DRUG IMPLANT; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHROPATHY; ARTICLE; BONE MARROW CELL; BONE REMODELING; CARTILAGE CELL; CELL FREE SYSTEM; CELL PROLIFERATION; DOWN REGULATION; ENZYME DEGRADATION; GENE EXPRESSION; IMMUNOHISTOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ADMINISTRATION AND DOSAGE; ANIMAL; CARTILAGE DISEASES; CHEMISTRY; DEVICE FAILURE ANALYSIS; DEVICES; DRUG IMPLANT; EQUIPMENT DESIGN; MATERIALS TESTING; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RABBIT; TISSUE REGENERATION; TISSUE SCAFFOLD; TREATMENT OUTCOME;

ORYCTOLAGUS CUNICULUS; PAA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARTILAGE DISEASES; CELL-FREE SYSTEM; COMBINED MODALITY THERAPY; DRUG IMPLANTS; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; GUIDED TISSUE REGENERATION; MATERIALS TESTING; RABBITS; STILBENES; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84926295490     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2014.08.022     Document Type: Article

References (44)

1. Zhen GH, Wen CY, Jia XF, Li Y, Crane JL, Mears SC, et al. Inhibition of tgf-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med 2013; 19: 704-12.
2. Emans PJ, van Rhijn LW, Welting TJM, Cremers A, Wijnands N, Spaapen F, et al. Autologous engineering of cartilage. Proc Natl Acad Sci USA 2010; 107: 3418-23.
3. Huey DJ, Hu JC, Athanasiou KA. Unlike bone, cartilage regeneration remains elusive. Science 2012; 338: 917-21.
4. Chung C, Burdick JA. Engineering cartilage tissue. Adv Drug Deliver Rev 2008; 60: 243-62.
5. Kandel RA, Grynpas M, Pilliar R, Lee J, Wang J, Waldman S, et al. Repair of osteochondral defects with biphasic cartilage-calcium polyphosphate constructs in a sheep model. Biomaterials 2006; 27: 4120-31.
6. Kock NB, Hannink G, van Kampen A, Verdonschot N, van Susante JLC, Buma P. Evaluation of subsidence, chondrocyte survival and graft incorporation following autologous osteochondral transplantation. Knee Surg Sport Tr A 2011; 19: 1962-70.
7. Lai JH, Kajiyama G, Smith RL, Maloney W, Yang F. Stem cells catalyze cartilage formation by neonatal articular chondrocytes in 3d biomimetic hydrogels. Sci Rep 2013; 3: 3553.
8. Asheesh Bedi RJWI. Cartilage resurfacing using synthetic composite plugs. Tech Knee Surg 2009; 8: 29-36.
9. Schagemann JC, Erggelet C, Chung HW, Lahm A, Kurz H, Mrosek EH. Cell-laden and cell-free biopolymer hydrogel for the treatment of osteochondral defects in a sheep model. Tissue Eng Part A 2009; 15: 75-82.
10. Burdick JA, Mauck RL, Gorman JH, Gorman RC. Acellular biomaterials: an evolving alternative to cell-based therapies. Sci Transl Med 2013; 5: 176ps4.
11. Liu WG, Deng C, McLaughlin CR, Fagerholm P, Lagali NS, Heyne B, et al. Collagen-phosphorylcholine interpenetrating network hydrogels as corneal substitutes. Biomaterials 2009; 30: 1551-9.
12. Shakibaei M, John T, Seifarth C, Mobasheri A. Resveratrol inhibits il-1 betainduced stimulation of caspase-3 and cleavage of parp in human articular chondrocytes in vitro. Ann N Y Acad Sci 2007; 1095: 554-63.
13. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007; 30: 1-6.
14. Wang J, Gao JS, Chen JW, Li F, Tian J. Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatol Int 2012; 32: 1541-8.
15. Wehling P, Reinecke J, Baltzer AA, Granrath M, Schulitz KP, Schultz C, et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Human Gene Ther 2009; 20: 97-101.
16. Sheu SY, Chen WS, Sun JS, Lin FH, Wu T. Biological characterization of oxidized hyaluronic acid/resveratrol hydrogel for cartilage tissue engineering. J Biomed Mater Res A 2013; 101: 3457-66.
17. Dave M, Attur M, Palmer G, Al-Mussawir HE, Kennish L, Patel J, et al. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and atp production. Arthritis Rheum 2008; 58: 2786-97.
18. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
19. Liu FC, Hung LF, Wu WL, Chang DM, Huang CY, Lai JH, et al. Chondroprotective effects and mechanisms of resveratrol in advanced glycation end productsstimulated chondrocytes. Arthritis Res Ther 2010; 12.
20. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M. Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol 2008; 75: 677-87.
21. Lei M, Liu SQ, Liu YL. Resveratrol protects bone marrow mesenchymal stem cell derived chondrocytes cultured on chitosan-gelatin scaffolds from the inhibitory effect of interleukin-1 beta. Acta Pharmacol Sin 2008; 29: 1350-6.
22. Li Y, Danmark S, Edlund U, Finne-Wistrand A, He X, Norgard M, et al. Resveratrol-conjugated poly-epsilon-caprolactone facilitates in vitro mineralization and in vivo bone regeneration. Acta Biomater 2011; 7: 751-8.
23. Dosier CR, Erdman CP, Park JH, Schwartz Z, Boyan BD, Guldberg RE. Resveratrol effect on osteogenic differentiation of rat and human adipose derived stem cells in a 3-d culture environment. J Mech Behav Biomed 2012; 11: 112-22.
24. Henrotin Y, Lambert C, Couchourel D, Ripoll C, Chiotelli E. Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products. Osteoarthr Cartilage 2011; 19: 1-21.
25. Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS Pharmscitech 2011; 12: 279-86.
26. Caddeo C, Manconi M, Fadda AM, Lai F, Lampis S, Diez-Sales O, et al. Nanocarriers for antioxidant resveratrol: formulation approach, vesicle selfassembly and stability evaluation. Colloid Surf B 2013; 111: 327-32.
27. Lucas-Abellan C, Fortea I, Lopez-Nicolas JM, Nunez-Delicado E. Cyclodextrins as resveratrol carrier system. Food Chem 2007; 104: 39-44.
28. Mont Kumpugdee-Vollrath YI. Increasing solubility of poorly water soluble drug resveratrol by surfactants and cyclodextrins. Adv Mater Res 2012; 418- 420: 2231-4.
29. Lu Z, Cheng B, Hu YL, Zhang YH, Zou GL. Complexation of resveratrol with cyclodextrins: solubility and antioxidant activity. Food Chem 2009; 113: 17-20.
30. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-82.
31. Li JJ, Shu Y, Hao T, Wang Y, Qian YF, Duan CM, et al. A chitosan-glutathione based injectable hydrogel for suppression of oxidative stress damage in cardiomyocytes. Biomaterials 2013; 34: 9071-81.
32. Wang W, Li B, Li Y, Jiang Y, Ouyang H, Gao C. In vivo restoration of fullthickness cartilage defects by poly(lactide-co-glycolide) sponges filled with fibrin gel, bone marrow mesenchymal stem cells and DNA complexes. Biomaterials 2010; 31: 5953-65.
33. Wang W, Li B, Yang JZ, Xin L, Li YL, Yin HP, et al. The restoration of fullthickness cartilage defects with bmscs and tgf-beta 1 loaded plga/fibrin gel constructs. Biomaterials 2010; 31: 8964-73.
34. Oshima Y, Harwood FL, Coutts RD, Kubo T, Amiel D. Variation of mesenchymal cells in polylactic acid scaffold in an osteochondral repair model. Tissue Eng Part C 2009; 15: 595-604.
35. Lee CH, Cook JL, Mendelson A, Moioli EK, Yao H, Mao JJ. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. Lancet 2010; 376: 440-8.
36. Ma T. Acellular biomaterials in mesenchymal stem cell-mediated endogenous tissue regeneration. J Mater Chem B 2014; 2: 31-5.
37. Fragonas E, Valente M, Pozzi-Mucelli M, Toffanin R, Rizzo R, Silvestri F, et al. Articular cartilage repair in rabbits by using suspensions of allogenic chondrocytes in alginate. Biomaterials 2000; 21: 795-801.
38. Diduch DR, Jordan LCM, Mierisch CM, Balian G. Marrow stromal cells embedded in alginate for repair of osteochondral defects. Arthroscopy 2000; 16: 571-7.
39. Ito Y, Ochi M, Adachi N, Sugawara K, Yanada S, Ikada Y, et al. Repair of osteochondral defect with tissue-engineered chondral plug in a rabbit model. Arthroscopy 2005; 21: 1155-63.
40. Zhang W, Chen JL, Tao JD, Jiang YZ, Hu CC, Huang L, et al. The use of type 1 collagen scaffold containing stromal cell-derived factor-1 to create a matrix environment conducive to partial-thickness cartilage defects repair. Biomaterials 2013; 34: 713-23.
41. Schinagl RM, Gurskis D, Chen AC, Sah RL. Depth-dependent confined compression modulus of full-thickness bovine articular cartilage. J Orthop Res 1997; 15: 499-506.
42. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 2006; 126: 677-89.
43. Hollander AP, Dickinson SC, Sims TJ, Brun P, Cortivo R, Kon E, et al. Maturation of tissue engineered cartilage implanted in injured and osteoarthritic human knees. Tissue Eng 2006; 12: 1787-98.
44. Diao H, Wang J, Shen C, Xia S, Guo T, Dong L, et al. Improved cartilage regeneration utilizing mesenchymal stem cells in tgf-beta1 gene-activated scaffolds. Tissue Eng Part A 2009; 15: 2687-98.